Citius Oncology, Stock Alpha and Beta Analysis
| CTOR Stock | 0.94 0.06 6.00% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Citius Oncology,. It also helps investors analyze the systematic and unsystematic risks associated with investing in Citius Oncology, over a specified time horizon. Remember, high Citius Oncology,'s alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Citius Oncology,'s market risk premium analysis include:
Beta 2.19 | Alpha (1.13) | Risk 6.54 | Sharpe Ratio (0.12) | Expected Return (0.79) |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Citius |
Citius Oncology, Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Citius Oncology, market risk premium is the additional return an investor will receive from holding Citius Oncology, long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Citius Oncology,. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Citius Oncology,'s performance over market.| α | -1.13 | β | 2.19 |
Citius Oncology, expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Citius Oncology,'s Buy-and-hold return. Our buy-and-hold chart shows how Citius Oncology, performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Citius Oncology, Market Price Analysis
Market price analysis indicators help investors to evaluate how Citius Oncology, stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Citius Oncology, shares will generate the highest return on investment. By understating and applying Citius Oncology, stock market price indicators, traders can identify Citius Oncology, position entry and exit signals to maximize returns.
Citius Oncology, Return and Market Media
The median price of Citius Oncology, for the period between Fri, Aug 30, 2024 and Thu, Nov 28, 2024 is 1.24 with a coefficient of variation of 22.69. The daily time series for the period is distributed with a sample standard deviation of 0.3, arithmetic mean of 1.33, and mean deviation of 0.26. The Stock received some media coverage during the period. Price Growth (%) |
| Timeline |
1 | Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology | 09/05/2024 |
2 | Acquisition by Holubiak Myron Z of 500000 shares of CTOR at 2.15 subject to Rule 16b-3 | 09/30/2024 |
3 | Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizum... | 11/11/2024 |
About Citius Oncology, Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Citius or other stocks. Alpha measures the amount that position in Citius Oncology, has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Citius Oncology, in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Citius Oncology,'s short interest history, or implied volatility extrapolated from Citius Oncology, options trading.
Build Portfolio with Citius Oncology,
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Citius Stock Analysis
When running Citius Oncology,'s price analysis, check to measure Citius Oncology,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Oncology, is operating at the current time. Most of Citius Oncology,'s value examination focuses on studying past and present price action to predict the probability of Citius Oncology,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Oncology,'s price. Additionally, you may evaluate how the addition of Citius Oncology, to your portfolios can decrease your overall portfolio volatility.